TNF and inflammatory bowel disease: TNF inhibitors, such as infliximab and adalimumab, play an important function in IBD treatment; however, up to 40% of patients experienced primary no respond to TNF inhibitors, and 23%–46% of patients experience secondary loss of response (5), underscoring the necessity for new, effective therapeutic strategies.